company background image
ACAD

ACADIA Pharmaceuticals NasdaqGS:ACAD Stock Report

Last Price

US$16.14

Market Cap

US$2.6b

7D

-5.0%

1Y

-2.8%

Updated

29 Sep, 2022

Data

Company Financials +
ACAD fundamental analysis
Snowflake Score
Valuation5/6
Future Growth6/6
Past Performance0/6
Financial Health5/6
Dividends0/6

ACAD Stock Overview

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders.

ACADIA Pharmaceuticals Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for ACADIA Pharmaceuticals
Historical stock prices
Current Share PriceUS$16.14
52 Week HighUS$28.06
52 Week LowUS$12.24
Beta0.67
1 Month Change0.12%
3 Month Change12.32%
1 Year Change-2.83%
3 Year Change-57.86%
5 Year Change-57.86%
Change since IPO140.90%

Recent News & Updates

Sep 12

FDA accepts Acadia's new drug application for Rett syndrome treatment trofinetide

Acadia Pharmaceuticals (NASDAQ:ACAD) on Monday said the U.S. FDA had accepted its new drug application (NDA) of investigational drug trofinetide for the treatment of Rett syndrome, a rare neurodevelopmental disorder. ACAD said the FDA granted the application a priority review and was set to decide on it by March 12, 2023, or the so-called Prescription Drug User Fee Act date. ACAD said the regulatory agency had informed the company that at this time it was not planning to hold an advisory committee meeting to review trofinetide. The NDA was supported by results from a phase 3 study which assessed the efficacy and safety of trofinetide in 187 girls and young women aged 5 through 20 with Rett syndrome. Rett syndrome causes a progressive loss of motor skills and language. It primarily affects females. ACAD stock +3.2% to $17.93 in afternoon trading.

Shareholder Returns

ACADUS BiotechsUS Market
7D-5.0%1.0%-3.1%
1Y-2.8%-25.8%-21.5%

Return vs Industry: ACAD exceeded the US Biotechs industry which returned -24.2% over the past year.

Return vs Market: ACAD exceeded the US Market which returned -20.3% over the past year.

Price Volatility

Is ACAD's price volatile compared to industry and market?
ACAD volatility
ACAD Average Weekly Movement6.3%
Biotechs Industry Average Movement11.1%
Market Average Movement6.9%
10% most volatile stocks in US Market15.7%
10% least volatile stocks in US Market2.8%

Stable Share Price: ACAD is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 6% a week.

Volatility Over Time: ACAD's weekly volatility (6%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1993540Steve Davishttps://www.acadia-pharm.com

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis. It’s pipeline include, pimavanserin, under phase 3 development for the treatment of Alzheimer’s disease psychosis, and negative symptoms of schizophrenia; Trofinetide, a novel synthetic analog, under phase 3 development for the treatment of Rett syndrome; ACP-044, a novel first-in-class orally administered non-opioid analgesic, under phase 2 development for treating acute and chronic pain; and ACP-319, a positive allosteric modulator of the muscarinic receptor, under phase 1 development for treating schizophrenia and cognition in Alzheimer’s.

ACADIA Pharmaceuticals Inc. Fundamentals Summary

How do ACADIA Pharmaceuticals's earnings and revenue compare to its market cap?
ACAD fundamental statistics
Market CapUS$2.61b
Earnings (TTM)-US$204.62m
Revenue (TTM)US$512.40m

5.1x

P/S Ratio

-12.8x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
ACAD income statement (TTM)
RevenueUS$512.40m
Cost of RevenueUS$344.87m
Gross ProfitUS$167.53m
Other ExpensesUS$372.15m
Earnings-US$204.62m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-1.26
Gross Margin32.70%
Net Profit Margin-39.93%
Debt/Equity Ratio0%

How did ACAD perform over the long term?

See historical performance and comparison